Oncology and Hematology News and Journal Articles
This article reviews the rationale for nanoparticle formulations of existing or previously investigated cytotoxic drugs, describe currently approved nanoparticle formulations of drugs, and discusses some of the most promising clinical trials currently underway.
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.
This video discusses the phase I trial of rovalpituzumab (Rova-T) for the treatment of patients with small-cell lung cancer.
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.
The journal ONCOLOGY includes a cartoon at the end of each issue. Here are the collected cartoons to date.